NCT05777655 Improving Adherence to Statin Therapy Through a Medication Management Application
| NCT ID | NCT05777655 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Essen |
| Condition | Atherosclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2023-02-17 |
| Primary Completion | 2028-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2023-02-17 with a primary completion date of 2028-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Interventional study to compare standard of care vs standard of care plus the use of a medication therapy management smartphone app (mediteo m+, Mediteo GmbH, Heidelberg) in patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * Atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +/- 10 days of enrolment) * Statin naivety * LDL-C \>100 mg/dl. No older than 21 days Exclusion Criteria: * Inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia) * Patient has no own smartphone (no device provided for this study) * Prior drug therapy to lower LDL-C within the last 30 days * Active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of \<6 months * Use of a digital therapy management application (including mediteo or mediteo m+) within the last month * Participation in another interventional trial * Pregnancy * Inability or unwillingness to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05777655 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05777655 currently recruiting?
Yes, NCT05777655 is actively recruiting participants. Contact the research team at benedikt.frank@uk-essen.de for enrollment information.
Where is the NCT05777655 trial being conducted?
This trial is being conducted at Essen, Germany.
Who is sponsoring the NCT05777655 clinical trial?
NCT05777655 is sponsored by University Hospital, Essen. The trial plans to enroll 250 participants.